Christina Allgeier
About Christina Allgeier
Christina Allgeier (age 53) is an independent director of STRATA Skin Sciences (SSKN) since October 2024. She is a CPA (Pennsylvania) with 24+ years in life sciences/medtech, currently a finance consultant with Danforth Advisors; prior roles include SSKN CFO & Treasurer (2015–2017) and Chief Accounting Officer at PhotoMedex (XTRAC’s prior owner) . The Board has affirmatively determined she is independent under NASDAQ rules, and she serves as the Board-designated “audit committee financial expert” .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| STRATA Skin Sciences, Inc. | Chief Financial Officer & Treasurer | Nov 2015 – Dec 31, 2017; consultant through Mar 31, 2018 | Brought SEC reporting and medtech operating experience to finance function |
| PhotoMedex (XTRAC prior owner) | Chief Accounting Officer | Pre-2015 (date not specified) | Public-company accounting leadership; relevant to XTRAC business integration |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Danforth Advisors | Finance Consultant | Current | Advisory finance role for life sciences firms |
Board Governance
- Independence: Independent under NASDAQ standards .
- Committee roles: Audit Committee Chair and designated Audit Committee financial expert; Member of Compensation/Nominating & Governance Committee .
- Meeting cadence/attendance: Board met 12x; Audit 7x; Comp/Nom/Gov 4x in the last fiscal year. All directors attended at least 75% of the Board/committee meetings on which they served . Each director in office attended the 2024 annual meeting .
| Committee | Role | Financial Expert | Independence |
|---|---|---|---|
| Audit Committee | Chair | Yes (Item 407(d)(5)) | Independent |
| Compensation/Nominating & Governance | Member | N/A | Independent |
Fixed Compensation
| Component | Amount | Period | Source |
|---|---|---|---|
| Fees earned (cash) | $15,562 | FY2024 | |
| Base Board Fee – Member | $40,250 | FY2024 schedule | |
| Base Board Fee – Chair | $70,250 | FY2024 schedule | |
| Audit Committee – Member | $8,000 | FY2024 schedule | |
| Audit Committee – Chair | $16,000 | FY2024 schedule | |
| Comp/Nominating/Gov – Member | $6,000 | FY2024 schedule | |
| Comp/Nominating/Gov – Chair | $15,000 | FY2024 schedule |
Note: The proxy includes these 2024 fee levels and notes “NEED TO UPDATE,” but the Director Compensation Table shows actual amounts paid, including Ms. Allgeier’s $15,562 for 2024 .
Performance Compensation
| Equity Element | Detail | Amount/Terms | Source |
|---|---|---|---|
| Annual stock/option awards (reported 2024) | Stock awards value | $0 | |
| New independent director equity | One-time option grant policy | 20,000 stock options (one-time grant) | |
| Clawback applicability | Awards subject to clawback/recoupment | Plan-level clawback; Board/committee policy |
No director-specific performance metrics (e.g., TSR targets) are disclosed for director equity; awards for new independent directors are option-based per policy .
Other Directorships & Interlocks
| Company | Role | Committee Roles | Notes |
|---|---|---|---|
| None disclosed | — | — | Ms. Allgeier’s biography lists no current public company directorships . |
Expertise & Qualifications
- CPA (Pennsylvania); BS in Accounting, Penn State University .
- 24+ years in life sciences/medical devices; significant SEC reporting and accounting expertise .
- Deep familiarity with SSKN/XTRAC business via prior CFO tenure and PhotoMedex CAO role .
- Designated Audit Committee financial expert; relevant for internal controls, audit oversight, and financial reporting quality .
Equity Ownership
| Item | Status | Source |
|---|---|---|
| Total beneficial ownership | Not listed individually in the March 31, 2025 beneficial ownership table; no share count disclosed for Allgeier | |
| Ownership as % of shares outstanding | Not disclosed for Allgeier | |
| Vested vs. unvested breakdown | Not disclosed for Allgeier | |
| Pledged shares | No pledging mentioned in the beneficial ownership section for Allgeier |
Related Party/Conflict Review
- Related-party oversight: The Audit Committee is responsible for reviewing and approving all related person transactions under Item 404 of Regulation S-K .
- Disclosures: In the provided proxy sections, no specific related-party transactions involving Ms. Allgeier are identified. The Board has determined she is independent under NASDAQ rules despite past employment as SSKN CFO (2015–2017) and prior consulting through March 2018 .
Shareholder Voting Signal (Election Outcome)
| Election (Annual Meeting) | Votes For | Votes Withheld | Broker Non-Votes | Source |
|---|---|---|---|---|
| Oct 29, 2024 – Director election (including Christina Allgeier) | 2,308,422 | 141,987 | 1,039,279 |
This indicates solid support levels for the slate that included Ms. Allgeier at the 2024 meeting .
Governance Assessment
- Strengths:
- Audit Committee Chair and “financial expert” designation provide strong financial oversight and signal governance rigor .
- Independence affirmed; committee mix (Audit Chair; Comp/Nom/Gov member) supports balanced oversight across financial reporting and compensation/governance .
- Attendance threshold met across the Board/committees; full director attendance at the 2024 annual meeting enhances engagement signals .
- Alignment/Compensation:
- Director pay primarily cash with modest equity exposure; policy provides a one-time 20,000 option grant for new independents, aligning interests with shareholders without excessive risk .
- Clawback provisions apply to awards under the incentive plan, supporting accountability .
- Watch items (not red flags based on current disclosures):
- Prior executive/consulting relationship with SSKN (ended 2018) could raise appearance questions; however, independence reaffirmed and no related-party transactions involving Ms. Allgeier are disclosed in the cited sections .
- Beneficial ownership not disclosed for Ms. Allgeier in the March 31, 2025 table; transparency would improve “skin-in-the-game” analysis .
Overall: Ms. Allgeier brings technical accounting depth and company-specific knowledge as Audit Chair/financial expert, with independence affirmed. Compensation structure and committee roles are consistent with governance best practices for a small-cap medtech issuer; no conflicts are disclosed in the provided materials .